Impact of new myeloma agents on the transfusion laboratory.

Jones, Andrew D; Moayeri, Morvarid; Nambiar, Ashok

Jones, Andrew D; Moayeri, Morvarid; Nambiar, Ashok.

Affiliation

Jones AD; UCSF Medical Center, Department of Laboratory Medicine, San Francisco, CA, USA. Electronic address: jonesa54@ccf.org.
Moayeri M; UCSF Medical Center, Department of Laboratory Medicine, San Francisco, CA, USA.
Nambiar A; UCSF Medical Center, Department of Laboratory Medicine, San Francisco, CA, USA.

Pathology ; 53(3): 427-437, 2021 Apr.

Article in En | MEDLINE | ID: mdl-33707006

Subject(s)

ADP-ribosyl Cyclase 1/antagonists & inhibitors; Antibodies, Monoclonal/therapeutic use; CD47 Antigen/antagonists & inhibitors; Membrane Glycoproteins/antagonists & inhibitors; Multiple Myeloma/drug therapy; ABO Blood-Group System; Blood Grouping and Crossmatching; Blood Platelets/drug effects; Blood Transfusion; Erythrocytes/drug effects; Humans; Immunotherapy; Laboratories; Liquid Biopsy; Multiple Myeloma/blood; Phenotype

Key words

Anti-CD38; DTT treatment; adsorption; anti-CD47; interference; phenotype-matched; pre-transfusion testing

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Membrane Glycoproteins / ADP-ribosyl Cyclase 1 / CD47 Antigen / Antibodies, Monoclonal / Multiple Myeloma Type of study: Guideline / Prognostic_studies Limits: Humans Language: En Journal: Pathology Year: 2021 Document type: Article

Fulltext

XML

PubMed Links

Search on Google